Acorda Therapeutics (ACOR) Tops Q4 EPS by 25c, Offers Guidance

Acorda Therapeutics (NASDAQ: ACOR) reported Q4 EPS of ($0.15), $0.25 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $50.5 million versus the consensus estimate of $44.58 million.

GUIDANCE:

Acorda Therapeutics sees Q1 2020 revenue of $130-160 million, versus the consensus of $149.2 million.

• Total product net revenue for the full year 2020 is expected to be $120 - $150 million, with total revenue expected to be $130 - $160 million. Product revenue excludes royalty revenue, primarily Fampyra royalty revenue obligations owed to Healthcare Royalty Partners.
• INBRIJA net revenue for the full year 2020 is expected to be $35 - $40 million.
• Expected INBRIJA U.S. annual peak sales has been revised to $300 - $500 million
• AMPYRA net revenue for the full year 2020 is expected to be $85 - $110 million.
• Operating expenses for the full year 2020 are expected to be $170 - $180 million, reduced from previous guidance of $180 - $190 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Sanofi jumps as Q1 key profit measure tops estimates; Citi reiterates Buy
• ATN International (ATNI) Misses Q1 EPS by 46c ; Offers Guidance